Company: STAA
Filing Date: 2025-10-06
Form Type: DEFA14A
Source: 0001193125-25-230935
Chunk: 6

Company: STAAR SURGICAL CO
Filing Date: 2025-10-06
Form: DEFA14A
Chunk 6
---
-forward growth profile does not support a higher valuation |

| • |     | STAAR’s stock price was well established in the $15.09 to $20.27 range in the five months prior to the 
 transaction announcement.                                                                              |

| • |     | The Alcon transaction provides a compelling premium on multiple measures. |

| • |     | 59% premium to STAAR’s 90-day VWAP as of the same date; |

| • |     | 47% premium to the median sell-side analyst price target of $19.00 per share as of just prior to the transaction 
 announcement; and                                                                                                |

| • |     | ~2.0x the median premium paid in comparable MedTech transactions. |

| • |     | Broadwood insists on using a flawed 20% forward growth number for its valuation of STAAR, despite knowing that 
 STAAR’s net sales have been contracting and that management is projecting 10% growth from 2026 to 2030.        |

With the recent expirationof the Hart-Scott-Rodino waiting period for the Alcon transaction, STAAR and Alcon continue to make progress toward the closing of the merger and look forward to completing the transaction so that its benefits can be realized for all stakeholders. The transaction is still anticipated to close in approximately six to 12 months of the initial merger agreement announcement on August 5, 2025, subject to customary closing conditions, including regulatory approval and approval by STAAR’s stockholders. STAAR will hold a virtual Special Meeting of Stockholders on October 23 at 8:30 a.m. (Pacific Time) to vote on the Alcon merger. Stockholders of record as of the close of business on September 12, 2025, are entitled to vote at the meeting. The STAAR Board of Directors unanimously recommends that all STAAR stockholders vote “FOR” the merger proposal on the WHITE proxy card TODAY. Stockholders with questions about voting their shares should contact STAAR’s proxy solicitor, Innisfree M&A Incorporated:

| • |     | For stockholders: +1 877-750-8233 
 (toll-free)                       |

| • |     | For banks and brokerage firms: +1 
 212-750-5833                      |

About STAAR Surgical STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses.